173 related articles for article (PubMed ID: 36179985)
1. Relationship Between Pretransplantation Nutritional Status and Outcome in Adults with Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
Orvain C; Byelykh M; Othus M; Sandmaier BM; Schoch G; Davis C; Appelbaum FR; Walter RB
Transplant Cell Ther; 2022 Dec; 28(12):846.e1-846.e9. PubMed ID: 36179985
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
3. Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis.
Michelis FV; Gupta V; Zhang MJ; Wang HL; Aljurf M; Bacher U; Beitinjaneh A; Chen YB; DeFilipp Z; Gale RP; Kebriaei P; Kharfan-Dabaja M; Lazarus HM; Nishihori T; Olsson RF; Oran B; Rashidi A; Rizzieri DA; Tallman MS; de Lima M; Khoury HJ; Sandmaier BM; Weisdorf D; Saber W;
Cancer; 2017 Jun; 123(11):2035-2042. PubMed ID: 28117898
[TBL] [Abstract][Full Text] [Related]
4. Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission.
Konuma T; Kanda J; Yamasaki S; Harada K; Shimomura Y; Terakura S; Mizuno S; Uchida N; Tanaka M; Doki N; Ozawa Y; Nakamae H; Sawa M; Matsuoka KI; Morishige S; Maruyama Y; Ikegame K; Kimura T; Kanda Y; Ichinohe T; Atsuta Y; Yanada M
Transplant Cell Ther; 2021 Apr; 27(4):334.e1-334.e11. PubMed ID: 33836881
[TBL] [Abstract][Full Text] [Related]
5. Pretransplantation Plasma ST2 Level as a Prognostic Biomarker of 1-Year Nonrelapse Mortality in Allogeneic Hematopoietic Cell Transplantation.
Gjærde LK; Ostrowski SR; Schierbeck F; Andersen NS; Friis LS; Kornblit B; Petersen SL; Schjødt I; Sengeløv H
Transplant Cell Ther; 2023 Feb; 29(2):97.e1-97.e6. PubMed ID: 36375798
[TBL] [Abstract][Full Text] [Related]
6. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
[TBL] [Abstract][Full Text] [Related]
7. Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission.
Walter RB; Sandmaier BM; Storer BE; Godwin CD; Buckley SA; Pagel JM; Sorror ML; Deeg HJ; Storb R; Appelbaum FR
Biol Blood Marrow Transplant; 2015 Feb; 21(2):373-8. PubMed ID: 25278455
[TBL] [Abstract][Full Text] [Related]
8. Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2.
Michelis FV; Messner HA; Atenafu EG; McGillis L; Lambie A; Uhm J; Alam N; Seftel MD; Gupta V; Kuruvilla J; Lipton JH; Kim DD
Bone Marrow Transplant; 2015 Nov; 50(11):1405-10. PubMed ID: 26168067
[TBL] [Abstract][Full Text] [Related]
9. Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Passweg JR; Labopin M; Christopeit M; Cornelissen J; Pabst T; Socié G; Russel N; Yakoub-Agha I; Blaise D; Gedde-Dahl T; Labussière-Wallet H; Malladi R; Forcade E; Maury S; Polge E; Lanza F; Gorin NC; Mohty M; Nagler A
Biol Blood Marrow Transplant; 2020 Apr; 26(4):659-664. PubMed ID: 31759159
[TBL] [Abstract][Full Text] [Related]
10. Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies.
Connor MP; Loren AW; Hexner EO; Martin ME; Gill SI; Luger SM; Mangan JK; Perl AE; McCurdy SR; Pratz KW; Timlin C; Freyer CW; Carulli A; Catania C; Smith J; Hollander L; Zebrowski AM; Stadtmauer EA; Porter DL; Frey NV
Transplant Cell Ther; 2023 Feb; 29(2):113-118. PubMed ID: 36336258
[TBL] [Abstract][Full Text] [Related]
11. Relative Telomere Length before Hematopoietic Cell Transplantation and Outcome after Unrelated Donor Hematopoietic Cell Transplantation for Acute Leukemia.
Wang Y; Wang T; Dagnall C; Haagenson M; Spellman SR; Hicks B; Jones K; Lee SJ; Savage SA; Gadalla SM
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1054-1058. PubMed ID: 28389255
[TBL] [Abstract][Full Text] [Related]
12. Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy.
Zuanelli Brambilla C; Lobaugh SM; Ruiz JD; Dahi PB; Goldberg AD; Young JW; Gyurkocza B; Shaffer BC; Ponce DM; Tamari R; Sanchez Escamilla M; Castillo Flores N; Politikos I; Scordo M; Shah GL; Cho C; Lin RJ; Maloy MA; Devlin SM; Jakubowski AA; Berman E; Stein EM; Papadopoulos EB; Perales MA; Tallman MS; Giralt SA; Smith M
Transplant Cell Ther; 2021 Sep; 27(9):771.e1-771.e10. PubMed ID: 34033977
[TBL] [Abstract][Full Text] [Related]
13. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185
[TBL] [Abstract][Full Text] [Related]
14. Reducing Mortality of Single-Unit Unrelated Cord Blood Transplantation for Relapsed Acute Myeloid Leukemia after a Previous Allogeneic Transplantation: A Real-World Retrospective Study Over the Past 19 Years in Japan.
Konuma T; Mizuno S; Harada K; Uchida N; Takahashi S; Eto T; Ota S; Kobayashi H; Katayama Y; Mori Y; Maruyama Y; Onizuka M; Yonezawa A; Kawakita T; Kimura T; Kanda Y; Fukuda T; Atsuta Y; Yanada M;
Transplant Cell Ther; 2022 Nov; 28(11):777.e1-777.e11. PubMed ID: 35964936
[TBL] [Abstract][Full Text] [Related]
15. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.
Walter RB; Gooley TA; Wood BL; Milano F; Fang M; Sorror ML; Estey EH; Salter AI; Lansverk E; Chien JW; Gopal AK; Appelbaum FR; Pagel JM
J Clin Oncol; 2011 Mar; 29(9):1190-7. PubMed ID: 21282535
[TBL] [Abstract][Full Text] [Related]
16. Comparison of reduced intensity and nonmyeloablative conditioning for adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation in first or second remission.
Walter RB; Sandmaier BM; Othus M; Orvain C; Rodríguez-Arbolí E; Oshima MU; Schoch G; Davis C; Joachim Deeg H; Storb R
Bone Marrow Transplant; 2023 Apr; 58(4):377-385. PubMed ID: 36577856
[TBL] [Abstract][Full Text] [Related]
17. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
18. Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT).
Maffini E; Labopin M; Beelen DW; Kroeger N; Arat M; Wilson KMO; Bay JO; Ganser A; Martin H; Passweg J; Kottaridis PD; Yakoub-Agha I; Porras RP; Wagner EM; Esteve J; Lanza F; Nagler A; Mohty M
Bone Marrow Transplant; 2022 Oct; 57(10):1556-1563. PubMed ID: 35835997
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with improved outcomes after second allogeneic hematopoietic cell transplantation for relapsed pediatric leukemia.
Menon NN; Jenkins LM; Cui H; Jenkins C; Anwer F; Yeager AM; Katsanis E
Ann Hematol; 2016 Mar; 95(4):637-44. PubMed ID: 26787415
[TBL] [Abstract][Full Text] [Related]
20. Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT.
Brands-Nijenhuis AV; Labopin M; Schouten HC; Volin L; Socié G; Cornelissen JJ; Huynh A; Ljungman P; Malard F; Esteve J; Nagler A; Mohty M
Haematologica; 2016 Feb; 101(2):248-55. PubMed ID: 26589909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
